 At this junction, DCC is not a pharmaceutical target.As DCC is not overexpressed in cancer and is present throughout the body, so it is not considered a good target for most types of cancer drugs.DCC is expressed at very low levels through most of the body but at higher levels in many areas of the brain, particularly in dopamine neurons.